Matheson


News and Insights

Print this page

Search News & Insights


Matheson advises Auxilium on its $2.6 billion merger with Endo

AUTHOR(S): George Brady, Tim Scanlon, Shane Hogan, John Ryan
PRACTICE AREA GROUP: Corporate, Tax
DATE: 09.10.2014

Matheson advised Auxilium Pharmaceuticals Inc. on its $2.6 billion merger with Endo International plc.

The transaction, which was announced on 9 October 2014, has been unanimously approved by the boards of directors of both companies. The transaction is valued at USD 2.6 billion, including the repayment and assumption of debt. The deal is expected to close in H1 2015 and is subject to shareholder and regulatory approval.

The Matheson team included corporate partners Tim Scanlon and George Brady, tax partner Shane Hogan and Head of US Offices, John Ryan. This continues Matheson’s track record of advising on high profile international M&A transactions. Matheson recently advised Questcor Pharmaceuticals on its $5.6 billion merger with Mallinckrodt and is advising Perella Weinberg Partners as financial adviser to Medtronic on its $42.9 billion acquisition of Covidien. Matheson also advised Actavis on its $8.5 billion acquisition of Dublin-based Warner Chilcott as well as advising Royalty Pharma on its $6.5 billion hostile bid for Elan Corporation, the Irish biotechnology company in 2013.

BACK TO LISTING

Matheson Snapshot


About cookies on our website

Following a revised EU directive on website cookies, each company based, or doing business, in the EU is required to notify users about the cookies used on their website.

Our site uses cookies to improve your experience of certain areas of the site and to allow the use of specific functionality like social media page sharing. You may delete and block all cookies from this site, but as a result parts of the site may not work as intended.

To find out more about what cookies are, which cookies we use on this website and how to delete and block cookies, please see our Which cookies we use page.

Click on the button below to accept the use of cookies on this website (this will prevent the dialogue box from appearing on future visits)